This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 1992 Apr;45(1):1-2.

doi: 10.1016/0090-8258(92)90481-w.

Intraperitoneal salvage chemotherapy in ovarian cancer: who is left to treat?

PMID: 1601329
DOI: 10.1016/0090-8258(92)90481-w

Editorial

Intraperitoneal salvage chemotherapy in ovarian cancer: who is left to treat?

R F Ozols. Gynecol Oncol. 1992 Apr.

. 1992 Apr;45(1):1-2.

doi: 10.1016/0090-8258(92)90481-w.

Author

PMID: 1601329
DOI: 10.1016/0090-8258(92)90481-w

No abstract available

PubMed Disclaimer

Comment on

Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon.
Markman M, Berek JS, Blessing JA, McGuire WP, Bell J, Homesley HD. Markman M, et al. Gynecol Oncol. 1992 Apr;45(1):3-8. doi: 10.1016/0090-8258(92)90482-x. Gynecol Oncol. 1992. PMID: 1601332 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Medical
- MedlinePlus Health Information